» Articles » PMID: 35259816

Biomaterial and Tissue-engineering Strategies for the Treatment of Brain Neurodegeneration

Overview
Date 2022 Mar 9
PMID 35259816
Authors
Affiliations
Soon will be listed here.
Abstract

The incidence of neurodegenerative diseases is increasing due to changing age demographics and the incidence of sports-related traumatic brain injury is tending to increase over time. Currently approved medicines for neurodegenerative diseases only temporarily reduce the symptoms but cannot cure or delay disease progression. Cell transplantation strategies offer an alternative approach to facilitating central nervous system repair, but efficacy is limited by low in vivo survival rates of cells that are injected in suspension. Transplanting cells that are attached to or encapsulated within a suitable biomaterial construct has the advantage of enhancing cell survival in vivo. A variety of biomaterials have been used to make constructs in different types that included nanoparticles, nanotubes, microspheres, microscale fibrous scaffolds, as well as scaffolds made of gels and in the form of micro-columns. Among these, Tween 80-methoxy poly(ethylene glycol)-poly(lactic-co-glycolic acid) nanoparticles loaded with rhynchophylline had higher transport across a blood-brain barrier model and decreased cell death in an in vitro model of Alzheimer's disease than rhynchophylline or untreated nanoparticles with rhynchophylline. In an in vitro model of Parkinson's disease, trans-activating transcriptor bioconjugated with zwitterionic polymer poly(2-methacryoyloxyethyl phosphorylcholine) and protein-based nanoparticles loaded with non-Fe hemin had a similar protective ability as free non-Fe hemin. A positive effect on neuron survival in several in vivo models of Parkinson's disease was associated with the use of biomaterial constructs such as trans-activating transcriptor bioconjugated with zwitterionic polymer poly(2-methacryoyloxyethyl phosphorylcholine) and protein-based nanoparticles loaded with non-Fe hemin, carbon nanotubes with olfactory bulb stem cells, poly(lactic-co-glycolic acid) microspheres with attached DI-MIAMI cells, ventral midbrain neurons mixed with short fibers of poly-(L-lactic acid) scaffolds and reacted with xyloglucan with/without glial-derived neurotrophic factor, ventral midbrain neurons mixed with Fmoc-DIKVAV hydrogel with/without glial-derived neurotrophic factor. Further studies with in vivo models of Alzheimer's disease and Parkinson's disease are warranted especially using transplantation of cells in agarose micro-columns with an inner lumen filled with an appropriate extracellular matrix material.

Citing Articles

Advances in Alzheimer's disease control approaches via carbon nanotubes.

Cai J, Li B, Zhang J, Feng G, Liu Y, Fan H Nanomedicine (Lond). 2024; 20(1):63-77.

PMID: 39607021 PMC: 11703444. DOI: 10.1080/17435889.2024.2432855.


Nanomedicine in Neuroprotection, Neuroregeneration, and Blood-Brain Barrier Modulation: A Narrative Review.

Krsek A, Jagodic A, Baticic L Medicina (Kaunas). 2024; 60(9).

PMID: 39336425 PMC: 11433843. DOI: 10.3390/medicina60091384.


Nanotechnology-driven therapies for neurodegenerative diseases: a comprehensive review.

Lopez-Espinosa J, Park P, Holcomb M, Godin B, Villapol S Ther Deliv. 2024; 15(12):997-1024.

PMID: 39297726 PMC: 11583628. DOI: 10.1080/20415990.2024.2401307.


Animal models in medical translation: the grand challenge of developing new treatments for human diseases.

Peplow P Front Med Technol. 2024; 6:1367521.

PMID: 38435848 PMC: 10904654. DOI: 10.3389/fmedt.2024.1367521.


One-step cell biomanufacturing platform: porous gelatin microcarrier beads promote human embryonic stem cell-derived midbrain dopaminergic progenitor cell differentiation and survival after transplantation .

Feng L, Li D, Tian Y, Zhao C, Sun Y, Kou X Neural Regen Res. 2023; 19(2):458-464.

PMID: 37488911 PMC: 10503631. DOI: 10.4103/1673-5374.377412.


References
1.
Mingorance A, Sole M, Muneton V, Martinez A, Nieto-Sampedro M, Soriano E . Regeneration of lesioned entorhino-hippocampal axons in vitro by combined degradation of inhibitory proteoglycans and blockade of Nogo-66/NgR signaling. FASEB J. 2006; 20(3):491-3. DOI: 10.1096/fj.05-5121fje. View

2.
Pang Z, Yang N, Vierbuchen T, Ostermeier A, Fuentes D, Yang T . Induction of human neuronal cells by defined transcription factors. Nature. 2011; 476(7359):220-3. PMC: 3159048. DOI: 10.1038/nature10202. View

3.
Wang T, Bruggeman K, Kauhausen J, Rodriguez A, Nisbet D, Parish C . Functionalized composite scaffolds improve the engraftment of transplanted dopaminergic progenitors in a mouse model of Parkinson's disease. Biomaterials. 2015; 74:89-98. DOI: 10.1016/j.biomaterials.2015.09.039. View

4.
Rodriguez A, Bruggeman K, Wang Y, Wang T, Williams R, Parish C . Using minimalist self-assembling peptides as hierarchical scaffolds to stabilise growth factors and promote stem cell integration in the injured brain. J Tissue Eng Regen Med. 2017; 12(3):e1571-e1579. DOI: 10.1002/term.2582. View

5.
Wang N, Jin X, Guo D, Tong G, Zhu X . Iron Chelation Nanoparticles with Delayed Saturation as an Effective Therapy for Parkinson Disease. Biomacromolecules. 2016; 18(2):461-474. DOI: 10.1021/acs.biomac.6b01547. View